Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
pemetrexed disodium, Quantity: 110.29 mg (Equivalent: pemetrexed, Qty 100 mg)
Accord Healthcare Pty Ltd
pemetrexed disodium
Injection, powder for
Excipient Ingredients: sodium hydroxide; mannitol; hydrochloric acid
Intravenous
1 vial per carton
(S4) Prescription Only Medicine
Malignant Pleural Mesothelioma,Pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,Non-Small Cell lung Cancer,Pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,Pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.
Visual Identification: A white to either light yellow or greenish yellow lyophilized solid in a clear glass vial; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius
Licence status A
2015-05-28